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Abstract: Benzodiazepines are some of the most commonly prescribed medications in the world.
These sedative-hypnotics can provide rapid relief for symptoms like anxiety and insomnia, but
are also linked to a variety of adverse effects (whether used long-term, short-term, or as needed).
Many patients take benzodiazepines long-term without ever receiving evidence-based first-line
treatments (e.g., psychotherapy, relaxation techniques, sleep hygiene education, serotonergic agents).
This review discusses the risks and benefits of, and alternatives to benzodiazepines. We discuss
evidence-based indications and contraindications, and the theoretical biopsychosocial bases for
effectiveness, ineffectiveness and harm. Potential adverse effects and drug-drug interactions are
summarized. Finally, both fast-acting/acute and delayed-action/chronic alternative treatments for
anxiety and/or insomnia are discussed. Response to treatment—whether benzodiazepines, other
pharmacological agents, or psychotherapy—should be determined based on functional recovery and
not merely sedation.
Keywords: benzodiazepine; sedative; hypnotic; anxiolytic; psychopharmacology; alprazolam;
clonazepam; evidence-based

1. Introduction
Benzodiazepines (BZDs) are some of the most commonly prescribed medications in the world [1,2].
However, they are commonly used in ways not supported by the literature. Here, we review their
historical and common uses, and the evidence for and against the use of benzodiazepines.
1.1. History of Benzodiazepines
The history of sedative-hypnotics extends back thousands of years to the early use of alcohol.
Likely because of its history and cultural perceptions, alcohol has not been categorized as a
sedative-hypnotic in the Diagnostic and Statistical Manual of Mental Disorders (DSM) [3]. However,
many consider alcohol to be a sedative-hypnotic because of its mechanism of action, synergy and
cross-tolerance with barbiturates and BZDs, and very similar intoxication and withdrawal phenomena.
Since the 1800s, several other sedative-hypnotics have been developed. After the introduction of
chlordiazepoxide in 1960, BZDs quickly became the most common “minor tranquilizer,” replacing
older agents like alcohol, chloral hydrate, paraldehyde, barbiturates and meprobamate. Compared to
these agents, BZDs were considered to have less side effects, toxicity, abuse (i.e., continued use despite
substance-related problems), physical dependence (i.e., tolerance and/or withdrawal), and suicide
potential. Unlike barbiturates, which were commonly abused (often intravenously to provide a
“rush”) and are lethal at levels 10 times the usual therapeutic dose, BZDs have a therapeutic ratio
above 100 [4]. While physicians recognized that BZDs did “not represent a panacea for all neurotic
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ills . . . does not eliminate the causes of intra- or extrapsychic stress . . . do not directly affect the
psychodynamic and environmental factors responsible for emotional problems . . . do not, at least in a
direct sense, affect the characterologic or personality side of the patient,” many were excited about the
hope that they could “facilitate problem solving, contribute to the de- and reconditioning of emotional
responses, and enable the patient to cope with intra- and extrapsychic stress more appropriately” in
conjunction with psychotherapy [5]. Many prescribers were led to believe that BZDs were harmless
and had no dependence risk [1,4]. BZDs were prescribed frequently and often long-term for various
conditions: Anxiety, insomnia, substance withdrawal, anesthesia, muscle tension, seizures, psychosis,
depression, narcosynthesis (aka the “BZD interview”) for combat neurosis, ordinary life stressors,
vague psychosomatic complaints, and even arrhythmias and myocardial infarction [1,5–9]. By the
1970s, BZDs were the most commonly prescribed medications in the world [1].
Unfortunately, the potential for abuse and dependence was rapidly discovered [10]. In 1975,
BZDs were placed on the Food and Drug Administration (FDA) restricted drug list, reflecting growing
concerns about abuse [5]. After years of patients and clinicians anecdotally reporting tolerance
and withdrawal with long-term use of even therapeutic doses, several controlled trials in the 1980s
confirmed that BZDs can cause dependence [1]. In 1990, the American Psychiatric Association (APA)
officially recognized the risk of BZD dependence [4,11]. With growing data and warnings about
BZDs as well as the arrival of safer, more effective anti-anxiety medications like selective serotonin
reuptake inhibitors (SSRIs) and the popularization of cognitive behavior therapy (CBT), BZD use
slowly declined after the mid-1980s (mostly due to the reduction of BZD use as anxiolytics as there
was little change in BZD use as hypnotics) [12,13]. In recent years, the Department of Veterans
Affairs (VA) has been particularly driven to replace BZD prescriptions with evidence-based treatments,
resulting in a significant reduction in BZD prescriptions from 1999 to 2009 [14]. VA Researchers [14]
speculated that “ideally, benzodiazepine use has decreased because veterans with Posttraumatic stress
disorder (PTSD) are receiving higher rates of evidence-based treatments for core symptoms, including
cognitive-behavioral therapy and adequate trials of first-line medications, thereby minimizing residual
symptoms and eliminating the need for adjunctive benzodiazepines.”
Despite recommendations against long-term BZD use (i.e., more than 2–4 weeks), many providers
continue to prescribe them for months or even years, allowing for dependence and diversion to occur [1,15].
Total BZD use actually increased from 1999 to 2014, largely driven by increases in long-term use [16].
For example, as many as 94% of PTSD patients using BZDs receive at least 30 day supplies and about
two-thirds receive at least 90 day supplies [14,17]. About 15% of the U.S. population take BZDs in any
given year and about 6% of the US population have abused sedative-hypnotics [12], drugs that—unlike
cannabis, amphetamines and opioids—exclusively originate from the medical system.
1.2. Common Uses Today
Since the introduction of SSRIs, BZDs are mostly used for anesthesia, alcohol or BZD withdrawal,
and the symptomatic treatment of anxiety and/or insomnia [18–20]. Many BZDs received FDA
approval (see Table 1) for the treatment of “anxiety states” or “anxiety disorders” prior to disorders
having specific diagnostic criteria first present in DSM-III in 1980. Therefore, BZD treatment represents
an off-label use (i.e., without FDA disease-specific approval) for most mental disorders. This is
especially true for PTSD, which was first officially recognized in DSM-III and was separated from
anxiety disorders in DSM-5 in 2013. Though the only FDA approved medications for PTSD are
sertraline and paroxetine (both antidepressants), of PTSD patients receiving pharmacotherapy, 65–90%
receive antidepressants, 37–74% receive sedative-hypnotics and 21–34% receive antipsychotics [20–22].
Therefore, PTSD patients were frequently prescribed medications not supported by evidence-based
clinical practice guidelines (CPGs), which generally discourage BZDs and marginally support
atypical antipsychotics. Most studies about BZD prescriptions are in participants with PTSD (likely
because of the VA’s increased interest in evidence-based treatment for veterans, who commonly
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have trauma-related and substance-related disorders), but one can imagine that there are parallels in
prescribing across diagnoses.
Table 1. Food and Drug Administration (FDA) approvals for benzodiazepines.
Benzodiazepine

Anxiety

flurazepam
chlordiazepoxide
diazepam
clorazepate
clobazam

+
+
+

clonazepam

Insomnia,
Short-Term

Alcohol
Withdrawal

Seizure

Other

+
+
+
+

+

estazolam
temazepam

+
+
+

Preoperative anxiety
Muscle spasms, preoperative sedation
Lennox-Gastaut syndrome (adjunct)
Panic disorder; periodic limb movement
disorder; neuralgia

+
+

lorazepam

+

oxazepam
alprazolam
triazolam
midazolam

+
+

+

+

Preoperative sedation;
chemotherapy-related nausea/vomiting

+
Panic disorder
+
Procedural sedation

There are four typical groups of BZD users: Older medically ill patients who are taking many
medications including BZDs usually prescribed by non-psychiatrists, panic disorder or agoraphobia
patients, patients with recurrent dysphoria with vague and chronic symptoms, and patients with
chronic sleep disturbances. The latter two groups have been found to be much more likely than the first
two groups to misuse BZDs (e.g., take with other substances like alcohol) [11]. Factors increasing the
likelihood of an individual being prescribed BZDs include: Comorbid psychiatric disorders (especially
anxiety disorders, PTSD, and borderline personality disorder) [17,20,22–25], substance use disorders
(SUDs) [20,22,23,26], inpatient psychiatric treatment [20,24], longer duration of disorder [14,17], more
VA disability compensation [17,20], concurrent opioid prescriptions [23,26], concurrent prescriptions
for other BZDs [26], and number of traumas [25]. Meanwhile, decreased BZD prescription for PTSD
patients correlates with increased prescription of antidepressants [24,27], trazodone [17], prazosin,
quetiapine, and non-BZD hypnotics [27]. While correlations with psychotherapy have not been studied,
one study predicted that the “expanded use of high-quality, evidence-based psychotherapy for PTSD,
insomnia, and other comorbidities could have contributed to declining reliance on benzodiazepine
prescribing” [23]. Studies conflict about howgender [17,22,23,26] and age [17,20,22,23,26] affect
BZD prescriptions.
When first-line serotonergic agents are initiated for anxiety, it is not uncommon for prescribers to
co-administer BZDs, despite this practice not being supported by the evidence and posingrisks [2,19,28].
Serotonergic agents (e.g., SSRIs, serotonin and norepinephrine reuptake inhibitors [SNRIs]) are
the first-line pharmacologic treatments for anxiety disorders, including panic disorder (PD) and
generalized anxiety disorder (GAD) [29]. These “antidepressants” (that are not only effective for
depression) typically take four to six weeks before they exert clinical effect, though in the treatment
of anxiety symptoms this delay can be even longer [30]. Further compounding this delay is that
antidepressants are not necessarily effective at starting doses and therefore during titration to an
effective dose a patient can remain symptomatic. Consequently, it can be months before anxiety
relief is experienced from an antidepressant regimen. BZDs are commonly used as adjuncts during
the first few weeks of starting a serotonergic agent with the hopes that once a therapeutic dose
is achieved, the BZD can be discontinued [31–33]. Unfortunately, there is no evidence to support
this practice, the combination may increase adverse effects without increasing therapeutic effects,
and it is not uncommon for patients to continue BZDs long-term in the presence or absence of the
antidepressant [2,34]. BZDs do not make SSRIs more effective when prescribed simultaneously, despite
conventional wisdom. There are also no long-term benefits, but there is a long-term risk of physical

J. Clin. Med. 2018, 7, 17

4 of 22

dependence (i.e., tolerance and/or withdrawal), associated with prescribing BZDs when initiating
SSRIs [2,12]. Despite many clinicians intending to taper/discontinue BZDs after the 4–6 weeks it
takes SSRIs to have their therapeutic effect, 12% of patients receiving this regiment continue BZDs for
over 6 months—sometimes in the absence of SSRIs—likely indicating the difficulty of discontinuing
BZDs once started. Despite the absence of efficacy and the evidence of risks, the rate of physicians
prescribing this way almost doubled between 2001 and 2014 [2].
It is common for psychiatrists to lament referrals from primary care after the primary care
prescriber initiated BZDs and then expects for the psychiatrist to assume responsibility for the
medication. Contrary to the prediction of the authors of one large study (n = 356,958) that primary
care providers were responsible for most BZD prescriptions, mental health providers prescribed BZDs
more than twice as often as other providers [21]. However, the study also found that BZD prescription
rates were highly variable between facilities. This conforms with suggestions that facility culture
can influence prescribing practices, and that a lack of awareness of CPGs and evidence is one of
the most common barriers to best practices. Provider and facility characteristics are an important
factor in BZD prescribing. Professional development activities, lectures, journal club presentations
and informal interactions among physician peers may influence local culture at the facility level
and encourage evidence-based practices [17]. However, the study [21] acknowledged the difficulty
prescribers face when they “inherit” patients who previously received BZDs from other prescribers
(many of whom started BZDs prior to CPGs), creating “an immediate tension” as providers attempt to
balance individual patient factors with the need to provide evidence-based care.
2. Evidence for Benzodiazepine Prescription
2.1. Evidence-Based Indications
The only mental disorders—not including alcohol/sedative-hypnotic withdrawal and
catatonia—for which there is an evidence basis for BZDs are PD, GAD, social anxiety disorder (SAD),
and insomnia [8,31–37]. For these four conditions, BZDs have only demonstrated efficacy and are only
recommended for short-term durations (i.e., less than 2–4 weeks) and for treatment-resistant cases
(i.e., after failing multiple first-, if not second-, line treatments).
Sedative-hypnotics can provide rapid relief for symptoms like anxiety and insomnia. Because
many anxiety and insomnia patients will be seen in primary care and medical specialty settings, it is
important that all providers be familiar with first-line evidence-based treatment recommendations.
BZDs are intended to be used for no more than 2–4 weeks in the treatment of severe anxiety and/or
insomnia that are resistant to multiple evidence-based treatments. Some argue to “limit benzodiazepine
prescriptions to emergency situations where a rapid symptomatic amelioration is required before
the onset of action of antidepressant treatment allows the reduction and finally the cessation of
benzodiazepines” [35].
Systematic reviews and CPGs generally recommend psychotherapy (e.g., CBT) and serotonergic
agents (e.g., SSRIs, SNRIs) as first-line treatments for anxiety disorders [19,33,38–44]. However, because
not all individuals respond or fully remit, or have adverse effects with these treatments, it is important
to know options for those who have continuing symptoms or do not tolerate first-line treatments [45].
BZDs are an evidence-based option for PD, GAD, and SAD patients who fail psychotherapy and
multiple serotonergic agents, or require adjunctive treatment when serotonergic agents are partially
effective but other adjuncts have failed.
In general, it is helpful, prior the onset of treatment, to determine if the impairment caused by an
anxiety disorder would be best ameliorated with short- or long-term treatment. For instances of anxiety
that are caused by infrequent, predictable inciting stimuli (e.g., fear of air travel, public speaking or
dental procedures) short-term BZD treatment may be the simplest, safest, and most effective course of
action. Though certainly non-BZD options should be considered (e.g., propranolol for performance
anxiety) as these options may have less potential for toxicity (e.g., cognitive dulling which would make
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it difficult to get to or think through a performance) and physical dependence. Where the experience
of anxiety is more enduring (e.g., GAD, PD) long-term pharmacologic treatment may be useful.
2.2. Theoretical Basis
Sedative/anxiolytic (i.e., anxiety-reducing) and hypnotic/soporific (i.e., sleep-inducing) effects
occur because BZDs potentiate the effects of gamma-aminobutyric acid (GABA), the primary inhibitory
neurotransmitter in the central nervous system (CNS). BZDs exert their effects allosterically on GABA-A
receptors by binding the BZD receptor complex. All BZDs interact with this complex and are capable of
producing both hypnotic and anxiolytic effects, despite specific FDA indications for particular disorders.
Therefore, selection of a particular agent for a given patient largely depends upon pharmacokinetic,
rather than pharmacodynamic properties [46,47]. When BZDs interact with GABA-A receptors, ion
channels open more frequently, increasing the inflow of chloride ions which increases membrane
polarization and inhibits neuron firing [4]. The result is CNS depression [12].
Some have postulated that underlying differences in GABA receptors can predispose individuals
to develop anxiety disorders, and/or that trauma/stressors can induce modulation or downregulation
of GABA receptors in those that develop anxiety disorders [48]. Dysfunction in the GABA system
(including BZD-GABA binding) in different brain areas have been theorized to correlate with common
anxiety symptoms: Amygdala (emotional modulation dysfunction and fear conditioning), prefrontal
cortex (attention and working memory deficits), hippocampus (memory formation dysfunction),
and striatum (salience reactivity and misinterpretation of aversivestimuli) [48–50]. While GABA
receptors are distributed throughout the CNS, the primary desired target for BZD activity for
anxiolytic effects is the amygdala and related circuits (e.g., the locus ceruleus which is implicated in
autonomic cardiovascular activity, periaqueductal gray which is implicated in autonomic motor activity,
the parabrachial nucleus which is implicated in autonomic respiratory activity, and hypothalamus
which is implicated in the endocrinological stress response and sleep regulation) [51]. Therefore, it is
theorized that BZDs can normalize these brain areas in individuals with hypoactive GABA activity
(e.g., provide inhibition in a hyperactive amygdala), thus relieving anxiety and improving sleep.
3. Evidence against Benzodiazepine Prescription
While there is some evidence for the efficacy of short-term BZDs in treatment-resistant cases of PD,
GAD, SAD and insomnia, BZDs are frequently overprescribed for other indications for which there is no
evidence of efficacy, to individuals who have contraindicated comorbid conditions, for longer periods
of time than are recommended, and before other first and second-line treatments are tried [52–57].
3.1. Conditions and Durations with No Evidence of Efficacy
Even in the conditions for which BZDs have proven efficacy—PD, GAD, SAD and insomnia—there
is no evidence of long-term efficacy.
Aside from PD, GAD, SAD and insomnia, no other mental disorders have an evidence-basis
for BZDs. To the contrary, PTSD [31,36,44,58] and phobias [59] have evidence of ineffectiveness or
even harm. Biological explanations for BZD-induced anxiety include discontinuation symptoms
(i.e., withdrawal or rebound symptoms resulting from GABA receptor desensitization and glutamate
receptor sensitization) and/or worsening of underlying anxiety pathophysiology (e.g., disrupting
normal hypothalamic-pituitary-adrenal [HPA] axis stress responses, and inhibiting serotonin
regulation) [58]. BZDs have demonstrated the ability to interfere with fear extinction [17,23,39],
which is critical for the improvement of anxiety and is likely why BZDs have been found to increase
fear conditioning with phobias [59] and to have fear-sensitizing effects in response tostress [23,60,61].
For many, BZDs—especially when used long-term—actually worsen anxiety.
BZD treatment for PTSD is particularly concerning because BZDs have no known preventative
value for PTSD and may actually increase the risk of developing PTSD 2–5 times among those with
trauma; BZD side effects overlap with several PTSD core symptoms (e.g., avoidance, negative mood,
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inattention, amnesia, recklessness, irritability); PTSD is commonly comorbid with conditions that
are contraindicated for BZDs (e.g., SUD, traumatic brain injury [TBI], depression); and BZDs can
inhibit trauma-focused psychotherapy by promoting avoidance of exposure, numbing trauma-related
emotions, and inhibiting of cognitive processing (all of which is necessary for recovery) [3,58,62–65].
For these reasons and the lack of any study supporting BZD efficacy for PTSD symptoms, most CPGs
(e.g., American Psychiatric Association, British Association for Psychopharmacology, International
Consensus Group of Depression and Anxiety, International Society for Traumatic Stress Studies,
Veterans Affairs/Department of Defense) recommend against the use of BZDs for PTSD [43,44,66–68].
Berger et al. [45] summarized: “There is no compelling scientific evidence of the effectiveness of
benzodiazepines either in the prevention of PTSD or in the treatment of its core symptoms although
clinical experience suggests that they may improve sleep and agitation, at least in the short term. These
limited advantages must be weighed against the marked potential for addiction that characterizes this
class of drugs, particularly considering that PTSD patients have higher rates of drug abuse/dependence
than the general population”.
There are no studies outside of case reports that support the use of BZDs as adjunctive or
symptomatic treatments. Additionally, some worry that “because benzodiazepines reduce anxiety
without addressing the underlying PTSD, clinicians may incorrectly believe the patient has improved,
thus delaying definitive PTSD care” [39]. High rates of comorbidity suggest that PTSD and SUDs
are functionally related, a concept supported by several studies indicating a pathway (likely related
to corticotropin-releasing hormone and norepinephrine) whereby PTSD precedes substance use [69].
Substance use is commonly a direct result of PTSD and often correlates with the amount of terror
felt during trauma [7]. In one large study (n = 274,297), while the strongest diagnostic predictor of
sedative-hypnotic prescription for PTSD was a comorbid anxiety disorder, 77.2% of those receiving
sedative-hypnotics did not have a comorbid anxiety disorder [20] and, therefore, did not have
an indicated diagnosis. Many researchers, clinicians and organizations have recommended that
pharmacotherapy—BZDs or otherwise—should not be used as a routine first-line PTSD treatment [33].
There are no studies to support the long-term use of BZDs for insomnia, and the evidence that
is supportive of short-term use is based on very few studies (which were insufficient to perform
a meta-analysis of triazolam) but triazolam was not considered first-line due to a higher risk for
“rebound anxiety” [37,57]. Some insomnia studies using BZDs demonstrate short-term efficacy
without evaluating long-term efficacy, some demonstrate no benefit after one day to several months
of use, and several demonstrate no statistical difference between BZDs and placebo even in the
short-term [13,37,58,70–72]. Likely explanations for the lack of long-term efficacy of BZDs for insomnia
include rebound insomnia, tolerance, and sleep architecture dysregulation. BZDs can directly worsen
sleep by disrupting sleep architecture, which may continue even months after discontinuation [4].
Several studies have demonstrated that even short-term BZD use can decrease sleep time, decrease
deep-stage/slow-wave sleep, increase rapid eye movement (REM) sleep latency, increase stage 2
non-REM sleep and decrease delta count [1,12,72,73]. Like alcohol, the sedating properties of BZDs
often deceive patients into thinking that BZDs improve sleep when, in actuality, they tend to induce
the early stages of sleep while inhibiting the deep, most restorative, stages of sleep. Fortunately,
BZDs do not permanently alter sleep architecture, as after an initial decrease in sleep time during
acute withdrawal, sleep parameters significantly improve following BZD discontinuation to levels not
significantly different from healthy controls [1,12,72].
3.2. Contraindicated Comorbid Conditions
While receiving BZDs for conditions without an indicated diagnosis is concerning, receiving
BZDs when contraindications are present is dangerous. Mental conditions for which BZDs
are contraindicated include SUDs, depression, suicidal ideation, bipolar disorder, psychosis,
and neurocognitive disorders (NCDs) including those due to TBI [58,74]. Unfortunately, each of these
have high comorbidity with anxiety disorders, for example: SUD (33–50%) [58,75], depressive disorders
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(10–55%) [3], and TBI (4–48%) [3,76]. Even more concerning, several studies have demonstrated
high rates of sedative-hypnotics among patients with contraindicated comorbid psychiatric disorders:
Depressive, substance use [20,22] and neurocognitive disorders [20,22,77]. In fact, anxiety patients with
these contraindicated disorders are usually more likely to receive sedative-hypnotics [20,22,23,26,77].
Because the development of BZD use disorder (BUD) with prescribed medications occurs in at
least 50% of patients with preexisting or active SUDs [1], BZDs are almost universally considered
contraindicated for patients with any history of SUDs (except in cases of acute alcohol or
sedative-hypnotic withdrawal).
Comorbid depression is particularly problematic. Because of high rates of comorbidity and
the large overlap of symptoms (e.g., negative thoughts, insomnia, irritability, fatigue, suicidality)
with depressive and anxiety disorders [19,35,38,66,78], a missed diagnosis of depression is possible
when treating only anxiety or insomnia. When the diagnosis is missed, a prescriber may be
less cautious than necessary about providing a BZD. BZDs do not prevent the development of
depression, can be depressogenic and can lead to suicide attempts [8,42,70,79,80]. BZDs have the
potential to cause or worsen depression, dysphoria, dissatisfaction with life, and suicidal thoughts
and behaviors [39,58,62,81]. Risk factors for attempted and completed suicide while using BZDs
include BZD intoxication, repeated BZD intoxication, high doses of prescribed BZDs, and underlying
depression [3,23,82]. While the anxiolytic and hypnotic effects of BZDs diminish as tolerance develops,
depression and impulsivity with high suicidal risk commonly persist and are “often interpreted as
an exacerbation or as a natural evolution of previous disorders and the chronic use of sedatives is
overlooked” [8]. Unlike antidepressants, in which activating effects usually improve with continued
treatment, BZD-induced depression is unlikely to improve. This is part of the reason BZDs may be
indicated for anxiety disorders like GAD and PD, but not for PTSD, which is not a pure anxiety disorder
as it also has features of depressive disorders and has a different underlying pathophysiology. Potential
explanations for BZD-induced depression include general CNS depression, prefrontal cortex [PFC]
inhibition (hypoactive PFC is implicated in depression, disinhibition and suicidality), BZD-induced
inhibition of central monoamine activity including serotonergic and noradrenergic, and withdrawal
dysphoria [58,83–85]. While BZD-induced depression may be exacerbated after discontinuation,
evidence suggests that mood significantly improves after the acute withdrawal period to levels better
than during use [8]. Modern practice guidelines (e.g., APA, The Department of Veterans Affairs and
the Department of Defense guidelines (VA/DoD)) for the treatment of major depressive disorder either
suggest using buspirone as an augmentation agent for anxiolysis or evaluating the treatment response
of an antidepressant prior to BZD trials [86]. Sedating antidepressants (e.g., doxepin, mirtazapine,
trazodone, and amitriptyline) can be effective for anxiety and/or insomnia especially with comorbid
depression [57]. Fortunately, the first-line treatments are the same for anxiety disorders, PTSD,
and depressive disorders: Psychotherapy and serotonergic agents.
In addition to the mental conditions above, BZDs have several other contraindications: BZD
hypersensitivity, pulmonary disease (e.g., sleep apnea, chronic obstructive pulmonary disease),
Parkinson’s disease, porphyria, hepatic disease, renal impairment, closed-angle glaucoma, myasthenia
gravis, children and adolescents less than 18 years old, pregnancy, and breast-feeding [74]. Sleep apnea
is of particular concern because it can be comorbid with or mimic anxiety disorders (e.g., insomnia,
fatigue, anxiety, and irritability). Similarly, pulmonary diseases in general, Parkinson’s disease and
porphyria are each associated with anxiety. Finally, obesity is a concern due to being associated with
reduced elimination of BZDs [74].
3.3. Adverse Effects
BZDs are linked to a variety of adverse effects, whether used long-term, short-term, or as
needed. While BZDs would be ideal anxiolytics if they could selectively inhibit the hyperactive
amygdala (implicated in anxiety), because GABA receptors are widely distributed throughout the
CNS, BZDs indiscriminately target the entire brain. This is particularly problematic for those
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areas of the brain that are already hypoactive in anxiety disorders, such as the PFC (implicated
in mood dysregulation including depression and anxiety, behavioral dysregulation including
disinhibition and irritability, and cognitive dysfunction including inattention and cognitive processing
of risk/stress/trauma) and hippocampus (implicated in amnestic effects and inhibited fear extinction).
However, global CNS inhibition also leads to adverse effects via every area of the brain including
motor, sensory, speech, and respiratory impairments [19,58,74,85]. Table 2 attempts to summarize
an exhaustive list of cognitive, emotional, behavioral, perceptual and physical adverse effects from
BZDs [1,3,4,8,11,15,24,31,59,74,78–80,83,87–91].
Table 2. Benzodiazepine adverse effects that overlap with core symptoms, associated symptoms and
common comorbidities of PTSD.
Overlap with
Anxiety

Example of Mental Disorders with Similar
Symptoms

dizziness (vertigo, lightheadedness/syncope)

+

panic, somatic, dissociative

nausea/vomiting

+

panic, somatic

+

panic, somatic

restlessness/psychomotor agitation

+

GAD, PTSD, mood, somatic

muscle pain/tension/spasms

+

GAD, PTSD, somatic

sensory (visuospatial impairments, photophobia, hyperacusis,
strange tastes, tinnitus, paresthesia/ numbness/burning)

+

panic, somatic

Benzodiazepine Adverse Effects
Physical

speech (dysarthria, slurred)
motor (incoordination/unsteadiness, ataxia, poor reaction time,
tremors, weakness, hyperreflexia, nystagmus, diplopia)

coryza/nasal congestion
rash

+

somatic

sexual (dysfunction, menstrual irregularities)

+

somatic, depressive, SUD, sexual

+

panic, PTSD, somatic

+

Somatic

sedation/drowsiness/fatigue

+

GAD, depressive, SUD, NCD

inattention/poor concentration

+

GAD, depressive, SUD, NCD

nightmares/intrusive thoughts

+

PTSD

memory impairments/amnesia

+

PTSD, dissociative, SUD, NCD

+

PTSD, panic, psychotic, dissociative, SUD, NCD
depressive, SUD, personality

+

PTSD, SUD, psychotic

blood dyscrasias
autonomic (brady- vs. tachy-cardia, hypo- vs. hyper-tension,
dyspnea/ respiratory depression vs. hyperventilation,
diaphoresis, fever/hyperpyrexia)
dependence (tolerance, withdrawal)
seizures

SUD

Cognitive

impaired judgment

SUD, NCD, psychotic, bipolar

perceptual (illusions, dissociation, de-realization, hallucinations)
suicidal ideations
homicidal ideations

SUD, personality

paranoia/hypervigilance
delirium/stupor/coma

SUD, NCD
Emotional

depression/dysphoria

+

PTSD, depressive, SUD

numbness/emotional anesthesia

+

PTSD, depressive, SUD, dissociative

anger/irritability/mood lability

+

PTSD, GAD, SUD, personality, bipolar

anxiety/phobias/panic

+

anxiety, PTSD, SUD

excitement/activation/euphoria

+

anxiety, SUD, bipolar

mania

SUD, bipolar
Behavioral

appetite/weight (anorexia, weight gain)

+

depressive, eating, SUD

insomnia

+

PTSD, GAD, depressive, SUD

avoidance/agoraphobia

+

anxiety, PTSD

impulsivity/disinhibition

+

PTSD, SUD, personality, bipolar

suicidality

+

PTSD, depressive, SUD, personality

aggression/hostility/rage/violence

+

PTSD, SUD, personality, bipolar

abuse/misuse/drug reinforcement

+

PTSD, SUD, personality
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3.3.1. Vulnerable Populations
Adverse effects are more likely to occur with elderly patients, NCDs, TBI, hepatic impairments,
renal impairments, pulmonary impairments (e.g., sleep apnea) and in combination with other CNS
depressants (e.g., alcohol, sedative-hypnotics, opioids, antihistamines, anticonvulsants, neuroleptics
and sedating antidepressants) [15,83].
Extra caution is recommended when prescribing BZDs to the elderly. Several considerations are
relevant to this recommendation. Specifically, disinhibition, falls, and respiratory depression are of
concern in the elderly given the higher prevalence of other chronic medical conditions. The elderly are
particularly sensitive to BZDs because of pharmacokinetic changes that prolong medication effects
(i.e., distribution, metabolism, elimination), increased use of additional medications that can compound
adverse effects, and increased presence of even minimal brain damage [8,13,73]. People of advanced
age may have impaired hepatic metabolism and this could lead to the accumulation of benzodiazepines
and their metabolites in the plasma and consequent toxicity. The lengthy half-life of diazepam often
makes that agent more risky in the elderly. Many clinicians favor the so-called “L.O.T. drugs” in this
population (lorazepam, oxazepam, and temazepam) as they do not require oxidative metabolism in
the liver and have no active metabolites. Agitation, associated with dementia is a common reason for
medical intervention in the elderly and benzodiazepines may be useful, especially in situations where
anxiety is prominent. Short-term use is the recommendation with special care needed to use only the
lowest effective dose. BZD toxicity in the elderly can cause cognitive impairment even with short-term
therapeutic doses [11]. After nicotine and alcohol, BZDs are associated with the greatest risk of SUD in
the elderly [13].
Additional concerns for women of child-bearing age include teratogenicity and breast-feeding.
BZDs have been labeled class D teratogens and are contraindicated in breast-feeding mothers [83].
The risk of BZDs in pregnancy is not entirely clear. There is evidence that BZDs cross the placenta to the
fetus and are secreted in breast milk to infants, although studies are mixed on specific consequences.
Early evidence suggested a heightened risk of facial anomalies though this finding has not been
consistently found and may have been confounded by other predisposing teratogenic etiologies
(e.g., anti-epileptic drugs) [92]. BZD use during pregnancy may cause preterm birth, low birth weight,
neonatal withdrawal, respiratory depression, temperature dysregulation, apnea, hypotonia, poor
feeding, sedation, lethargy, weight loss, cleft palates, cardiac malformations, neural tube defects, limb
deficiencies, anal atresia, floppy baby syndrome, lower Apgar scores, and impede the progress of
childbirth [15,31,93–95]. BZD use during breastfeeding may cause sedation, weight loss, respiratory
depression (especially with long-acting BZDs), and withdrawal (especially with short-acting BZDs) in
children [93]. Thus, as with other clinical scenarios, the use of BZDs should include an assessment of
the risks and benefits, and in pregnancy the consideration of risks should be extended to the unborn
child. This includes the risks and benefits of prescribing BZDs and the risks of untreated mental illness
in pregnancy, which can carry a host of downstream effects. Complicated mental health in pregnancy
represent an appropriate time to engage a psychiatrist for collaboration or consultation.
3.3.2. Tolerance
A major disadvantage with BZDs is that tolerance to their therapeutic effects develop relatively
quickly while many adverse effects persist. Tolerance develops to hypnotic effects within days to weeks,
to myorelaxant effects within weeks, to anticonvulsant effects within weeks to months, and to anxiolytic
effects within months [1,8,83,96]. This explains why patients commonly increase dosage over time and
many eventually take more than one type of BZD after the first loses effectiveness [1,3,4,73,79]. While
therapeutic effects are subject to tolerance, adverse effects often are not, with cognitive, depressogenic,
and disinhibiting effects typically persisting long-term when present and increasing in risk if doses
are increased in response to therapeutic tolerance [8]. Because tolerance to brain stem depressant
effects develop more slowly than tolerance to sedating effects, patients may take more BZDs to achieve
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desired effects (e.g., hypnotic, anxiolytic or even euphoria in recreational abusers) which may cause
sudden respiratory depression, hypotension and/or death [3].
BZD tolerance develops as the result of long-term alterations of the intraneural gene expression
and function of GABA receptors, likely including downregulation of BZD binding sites on GABA-A
receptors (similar to alcohol), uncoupling of the allosteric linkage of the BZD-GABA receptor complex,
and changes in receptor subunit turnover [1,4,8,83,96]. Chronic BZD-induced enhancement of GABA
also likely results in a compensatory sensitization of excitatory systems (including glutamate) [1,97].
3.3.3. Cognitive, Emotional and Behavioral Adverse Effects
Many adverse effects of BZDs overlap with symptoms associated with mental disorders (see Tables 3
and 4). This overlap may make it difficult to determine if symptoms are due to underlying anxiety
disorders or BZDs. Symptoms with specificity for sedative-hypnotic toxicity include nystagmus,
slurred speech and unsteady gait [4]. Overlapping symptoms and adverse effects indicate that
BZDs may synergistically worsen underlying anxiety (which may be misattributed to a primary
worsening of underlying anxiety). Giving credence to this concern, several studies have demonstrated
that psychiatric symptoms, cognitive performance and general physical health improve after BZD
discontinuation (especially in the elderly) [1].
Table 3. Benzodiazepine-induced disorders in the Diagnostic and Statistical Manual of Mental
Disorders, 5th Edition [3].

Psychotic Disorder
Bipolar Disorder
Depressive Disorder
Anxiety Disorder
Sleep Disorder
Sexual Dysfunction
Delirium
Neurocognitive Disorder

Disorder with Onset
During Intoxication

Disorder with Onset
During Withdrawal

+
+
+

+
+
+
+
+
+
+
+

+
+
+
+

Persisting Disorder

+

Mental health patients commonly have inattention (e.g., GAD, PTSD, depression), and amnesia
(e.g., PTSD, dissociative disorders). Therefore, it is particularly disturbing that cognitive impairments
are among the adverse effects caused by BZDs (i.e., benzodiazepine-induced neurocognitive disorder).
While cognitive effects can occur as part of BZD intoxication, withdrawal or delirium, they can also
occur as a direct effect of BZDs [3]. Cognitive impairments are more common with high doses and/or
long-term use of BZDs, but can also be caused by low doses, short-term use and even single daily
doses (especially in the elderly) [3,13]. While the most common cognitive adverse effects of BZDs
(sedation and drowsiness) often improve as tolerance develops, many cognitive impairments persist
with continued use: Attention, concentration, learning, working memory, episodic memory, semantic
memory, verbal memory, nonverbal memory, procedural memory, general intelligence, problem
solving, verbal reasoning, procedural reasoning system, speed of processing, sensory processing,
visuospatial abilities, motor performance and psychomotor speed [1,6,8,12,15,71,83]. In the elderly,
these symptoms may be mistaken for an unrelated progressive dementia [1,3]. In fact, BZDs can
cause dementia which persists after discontinuation of use [3,98]. In fact, elderly patients often
attribute memory problems to age rather than BZDs and about 10% of elderly patient referred to
memory clinics have cognitive impairments that are substance-induced, often due to BZDs [13]. Risk
factors for BZD-induced neurocognitive disorder include older age (especially persistent use after
50 years old) [3,6,12,23], other substance use (especially alcohol), other NCDs (especially TBI), delirium
(in which even very low doses of BZDs may be intoxicating), longer use and primary psychiatric
disorders (especially PTSD, psychotic, depressive and bipolar disorders) [3]. For these and other
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reasons, BZDs are contraindicated in patients with a history of SUD, NCD, TBI and depression.
Finally, some have argued that BZDs need to be discontinued prior to psychotherapy because the
cognitive effects of BZDs decreased psychotherapy effectiveness, likely due to reduced ability to
cognitively process and remember material presented in therapy [45]. Fortunately, several studies have
demonstrated that cognition improves after discontinuing BZDs (especially working and episodic
memory, visuospatial search abilities, information processing, attention and simple reaction time) [13].
While cognition usually slowly recovers after BZD discontinuation, like with alcohol, these effects can
persist after an extended period of abstinence (i.e., benzodiazepine-induced persisting neurocognitive
disorder, previously called benzodiazepine-induced persisting amnestic disorder) [1,3,6,12].
BZD use for anxiety disorders can be problematic because anxiety, panic attacks, phobias and
social avoidance are among the adverse effects of BZDs. While BZDs may provide short-term relief
for anxiety, there is often a paradoxical long-term worsening of anxiety. Similar concepts have been
studied with nicotine (which is associated with worse anxiety with chronic use and improvement after
discontinuation) [99,100] and opioids (i.e., opioid-induced hyperalgesia, in which chronic opioid use
makes patients more sensitive to pain) [101,102]. Nevertheless, patients often believe these substances
are helping, mistaking the temporary relief of withdrawal symptoms for improvement of baseline
symptoms. It seems patients are much more adept at detecting the immediate impact of a BZD on
anxiety symptoms as opposed to detecting the long-term deterioration in mood or worsening of
anxiety. Potential explanations for BZD-induced anxiety disorder include: Rebound or withdrawal
anxiety (i.e., after tolerance develops to the anxiolytic effects of BZDs, they no longer treat baseline
anxiety but only treat discontinuation symptoms at best returning anxiety levels back to their pre-BZD
baseline) [1,8]; BZDs increasing fear responses after stressful exposures likely by fear-sensitization and
generalizing conditioneddefeat [60,61,103,104]; BZDs being associated with a loss of self-confidence
in one’s ability to cope with stressors without medications [83]; and BZDs indirectly worsening
anxiety by promoting avoidance, preventing fear extinction, inhibiting cognitive processing of past
traumas and present risk assessment, and inhibiting the process of desensitizing individuals to
anxiety through both therapeutic and natural exposure [7,17,23,25,27,39,58,59]. During the 1980s,
many behavioral therapists and researchers began realizing that BZDs reduce the therapeutic effects
of exposure. This undercut the purpose of exposure therapy: Gradually decrease anxiety through
repeated exposure to anxiety-provoking stimuli. It also challenged an assumption made since the
1960s that a drug-induced low-anxiety state accompanying anxiety-provoking stimuli would lead to
faster fear extinction. Several studies suggest that “patient attribution of fear reduction to the drug
rather than to improvement in coping may result in a loss of gains after withdrawal of the drug” [59].
Therefore, BZDs may directly worsen avoidance and indirectly worsen anxiety by inhibiting emotional
and memory processing during exposure (therapeutic or natural), decreasing learning efficiency
and decreasing fear extinction. Avoidance is an important consideration because, although patients
often present complaining about arousal and autonomic symptoms, it is arguably the most disabling,
the most difficult to treat, and the most predictive of poor outcome. Once physical dependence
develops, the affective states that are numbed with sedatives become more intense during withdrawal
states causing patients to wrongly believe that the withdrawal state is their baseline and believe
that they need the substance. While anxiety may be exacerbated during acute withdrawal, evidence
suggests that patients have significantly less anxiety five weeks after discontinuation then they had
during BZD use (when users often subjectively report being less anxious than they were prior to using),
and avoidance and social functioning improve within one year of BZD discontinuation [1,8].
Insomnia is one of the most common chief complaints of patients with mental disorders, and sleep
deprivation can cause fatigue, irritability, inattention, depression, anxiety, dysfunction, and reduced
quality of life [21,63,73]. Therefore, it is particularly disturbing that BZD-induced sleep disorder,
insomnia and nightmares are among the adverse effects of BZDs. While BZDs may provide short-term
relief for insomnia, there is often a paradoxical long-term worsening of sleep. After tolerance develops
to the hypnotic effects of BZDs, it is likely that they no longer treat baseline insomnia but only treat

J. Clin. Med. 2018, 7, 17

12 of 22

rebound and withdrawal insomnia (i.e., benzodiazepine-induced sleep disorder), at best allowing
the patient to sleep as they did prior to BZD use [1,8,11]. Many patients claim they cannot sleep
without BZDs, not realizing they are only preventing rebound insomnia caused by chronic BZD use.
One randomized control trial concluded “ineffectiveness of BZDs in aiding sleep is also suggested
by the significantly positive correlations between measures of BZD intake (dose, cumulative dose)
and patient’s ratings of sleeping problems. In the withdrawers at baseline, the higher the nightly dose
of BZD the greater the rating of sleep problems” [13]. In addition to rebound insomnia, BZDs often
exacerbate sleep disturbances by directly disrupting sleep architecture (like alcohol). Sleep architecture
may continue to be disrupted even months after BZD use [4]. Several studies have demonstrated
that even short-term BZD use can worsen several sleep parameters: Decreasing sleep time, increasing
rapid eye movement (REM) sleep latency, decreasing slow wave sleep (stages 3 and 4 non-REM sleep),
increasing stage 2 non-REM sleep and decreasing delta count [1,12,72,73]. After an initial decrease in
sleep time during acute BZD withdrawal, sleep parameters significantly improve (especially in the
elderly) to levels not significantly different from healthy controls: Sleep quality, increased slow wave
sleep and increased delta count [1,8,12,13,72]. This indicates that BZD use can cause poor sleep, but
sleep usually recovers after discontinuation.
Many patients with mental health problems struggle with irritability, aggression, violence,
suicidality, and/or self-destructive or reckless behavior. Therefore, it is particularly disturbing that
the list of potential BZD adverse effects include all of these, as well as poor judgment and behavioral
disinhibition. While BZDs may provide acute improvement of agitation, there is often the potential for
worsening with regular use. While alprazolam has the strongest link with aggression, it may occur
with any BZD (including the supposedly “safe” clonazepam) [105]. A large long-term cohort study
concluding that “our results provide additional support for discouraging long-term benzodiazepine
use to manage core symptoms of PTSD” [106]. In addition to rebound irritability, BZDs can cause
“paradoxical reactions” (e.g., disinhibition, impulsivity, excitement, irritability, aggression, hostility,
rage attacks, violence, homicidal ideations, suicidality) [24,83,105]. The proposed mechanisms of
BZD-induced violence is similar to that of alcohol, including PFC inhibition and systemic inhibition of
serotonin (which is associated with anger, impulsivity and violence at low levels) [84]. While evidence
suggests that BZD-induced violence is rare, it is usually severe when it does occur [105]. Like with
alcohol, BZD-induced disinhibition can result in subsequent interpersonal (e.g., arguments, fights,
and inappropriate sexual or aggressive behavior), medical (e.g., physical risks like fights, and driving
an automobile or operating a machine while impaired) and/or legal problems (from the above as well
as neglect of children) [3]. Risk factors for paradoxical reactions with BZDs include other substance
use (especially alcohol) [24,90,105], neurocognitive disorders (especially TBI) [17,84,105], a history
of disinhibition or impulsivity (especially with borderline personality disorder) [39,105,106], anxiety
disorders [24,90], older age [31], learning disabilities [105], and motivational drive [107]. Unfortunately,
some of these factors (substance use, anxiety and personality disorders) also correlate with increased
BZD prescription for PTSD patients. For these and other reasons, BZDs are contraindicated in
patients with a history of SUD, TBI or a history of impulsivity or violence [39,44]. However, there
are reports of patients engaging in uncharacteristic behaviors (e.g., aggressive, destructive, sexually
inappropriate and criminal) that only occur after BZD use, without any history of similar behaviors,
and usually improve after discontinuation [15,90,105]. While the anxiolytic and hypnotic effects of
BZDS disappear as tolerance develops, irritability, anger and impulsivity with high suicidal risk
commonly persist [8]. Furthermore, BZD-induced irritability may be exacerbated during withdrawal,
evidence suggests that irritability significantly improves after the acute withdrawal period to levels
better than during use [8,13].
3.3.4. Physical Adverse Effects
Sedation (including daytime drowsiness from a previous night’s dose) is the most common
BZD adverse effect [12]. Other common adverse effects include unsteadiness, impaired psychomotor
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speed and accuracy, cognitive impairment and slurred speech. BZDs can be fatal, whether directly
by overdose (usually due to synergistic respiratory depression when combined with other CNS
depressants) or indirectly by injury (usually as the result of BZD-induced cognitive impairment,
inattention, incoordination, unsteadiness, delayed reaction time, visuospatial impairments, behavioral
disinhibition and/or poor judgment) [4]. BZDs—from both nonmedical use and use as prescribed—are
associated with emergency department visits, typically due to overdoses (whether suicidal, accidental
and/or recreational) or injuries (e.g., falls, fights, motor vehiclecollisions) [1,3,11,13,23,31,71,105]. BZDs
increase the risk of fractures 50–110%, with no difference in risk between short-acting and long-acting
BZDs, and combining BZDs with other substances more than doubles the risk of injury [12]. These
risks are particularly disturbing for anxiety patients, for which comorbid substance use is common
and who often already have difficulty concentrating, irritability or impulsivity.
3.3.5. Dependence, Misuse, Abuse and Addiction
BZDs have been shown to be relatively efficacious for the short-term treatment of GAD, PD, SAD and
insomnia, but long-term efficacy is unproven while the risk of physical dependence and addiction is. “Like
alcohol, these agents are brain depressants and can produce similar substance/medication-induced
and substance use disorders” [3]. There has been much debate and confusion about what constitutes a
BZD use disorder in patients prescribed BZDs. Some have tried to clarify this by distinguishing
non-mutually exclusive terms: Physical dependence, misuse, recreational abuse and addiction.
The DSM-5 nomenclature is consistent with these distinctions for prescribed medications (e.g., opioid
analgesics, sedatives, stimulants), exempting tolerance and withdrawal from the diagnostic criteria for
SUD when these are the only symptoms present and medications are taken as prescribed [3]. Below
we define and differentiate various substance-related terms.
Physical dependence is the presence of tolerance and/or withdrawal. Of those prescribed therapeutic
doses of BZDs long-term, 58–100% inadvertently become physically dependent (therapeutic dose
dependence) [1,12]. Iatrogenic dependence is more likely to occur with high doses and/or short acting
BZDs, but can occur with any BZD prescription [1,26,31]. As tolerance develops, some patients are able
to persuade providers to increase their dose (prescribed high-dose dependence). Even patients who
recognize the long-term ineffectiveness of BZDs often continue to take them to stave off withdrawal
symptoms, which are often mistaken for baseline anxiety [1]. With increased usage, tolerance and the
potential for withdrawal worsen. Both BZD tolerance and withdrawal can be explained by the chronic
desensitization of GABA receptors and sensitization of glutamate receptors. Considering that low GABA
receptor sensitivity and hyperactive glutamate are implicated in anxiety [1,97], this would imply that
chronic BZD use could actually exacerbate the pathophysiology of anxiety rather than improves it.
Prescription medication misuse is the use of medications differently than prescribed (e.g., higher
doses, increased frequency, combined with alcohol, etc.), obtaining medications from several providers
without informing them of the others (i.e., “doctor shopping”), or diversion (i.e., giving, selling or
trading medications to others). Misuse is more likely to occur with the elderly, chronic pain and a
history of SUD [91]. BZDs can cause drug reinforcement and misuse in patients without histories of
SUD in conditions of continuous BZD availability, especially in patients with anxiety, insomnia and
histories of moderate alcohol consumption [91]. As BZD tolerance develops, there is often a gradual
increase in the frequency of self-administration beyond provider recommendations, which may be
subtle and mistaken for appropriate use [91]. Some patients combine BZDs with alcohol when they are
not able to obtain desired therapeutic effects due to tolerance [83]. “The individual is likely to continue
to justify use on the basis of his or her original symptoms of anxiety or insomnia, but substance seeking
behavior becomes more prominent, and the individual may seek out multiple physicians to obtain
sufficient supplies of the medication” [3]. While some solely rely on providers for BZDs, others obtain
extra medications from the black market (generally supplied by patients who divert prescriptions) [1].
Recreational abuse is the intentional use of medications to produce intoxication (a “high”).
Short-acting BZDs are more likely to be used for intoxicating purposes, although long-acting BZDs
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(including the supposedly “safe” clonazepam) can also produce a high [3,83]. BZDs can be used as
the primary drug of choice, but they are used in conjunction with other substances about 80% of the
time [1,83]. In combination with other CNS depressants, like alcohol, cannabis or opioids (including
methadone), BZDs are often used by substance users to enhance intoxication (i.e., a “boost”) [3,4,83].
These combinations can be lethal, whether by accidental or deliberate overdose [3]. Concurrent alcohol
use is particularly concerning because of availability, cross-tolerance with BZDs, and because providers
are commonly unaware of alcohol use [12]. This is a problem because patients prescribed BZDs for
alcohol-induced anxiety or sleep disorders (whether the provider recognizes that the symptoms are
alcohol-related or not) are at increased risk of misusing BZDs [3,4]. Many substance users also use
BZDs to alleviate unpleasant effects associated with other substances, including self-treating opioid
withdrawal (i.e., a “fix”) and stimulant intoxication (i.e., a “come down”) [1,3,83]. The combination of
stimulant-induced wakefulness/agitation and BZD-induced cognitive impairments (e.g., judgment,
memory) can result in unpredictable behavior [4]. Recreational abusers are more likely to use BZDs by
insufflation (“snorting”) or intravenously (which is associated with its own inherent medical risks, like
infections) [1,3,15,105]. Higher doses, combining BZDs with other substances, and non-oral use all
increase the risk of overdose.
Addiction is a chronic pattern of compulsive drug-seeking associated with a loss of
control, preoccupation and anticipation, and continued use despite psychosocial dysfunction
anddistress [3,8,12,108]. Table 4 describes BUD and related disorders. When in the context of
only taking BZDs as prescribed, BUD should only be diagnosed when these factors are present
(i.e., not based on tolerance or withdrawal alone) [3]. Risk factors for developing BUD include
pre-existing or active SUDs (especially alcohol, sedative-hypnotics, cannabis, opioids and stimulants),
family history, medical availability, early onset of use, chronic medical conditions, chronic insomnia,
chronic dysphoria, impulsivity, and borderline or dependent personality disorders [1,3,8,11,12,17,90].
Unfortunately, some of these factors—particularly SUDs and borderline personality disorder—also
correlate with increased BZD prescriptions [20,22,23,25,26]. BUD is almost universally iatrogenic due
to widespread over-prescription [1]. Because BZDs are exclusively manufactured by pharmaceutical
companies (unlike most other substances), the prevalence of dependence correlates with its medical
availability [3,4]. In addition to prescriptions, BZDs can be obtained through the internet, the black
market (“the street”) or theft (e.g., from manufacturers, delivery services, hospitals, clinics, pharmacies
or patients’ medicine cabinets).
Table 4. Benzodiazepine-related disorders in the Diagnostic and Statistical Manual of Mental Disorders,
5th Edition.
Benzodiazepine Use Disorder
Duration of at least 2 signs/symptoms
within a 12-month period
use larger amounts or over a longer
period of time than intended
(2) desire to cut down use
(3) a great deal of time spent obtaining
(4) cravings
(5) failure to fulfill major role obligations
(6) use despite social or
interpersonal problems
(7) important activities are given up
or reduced
(8) use in physically hazardous situations
(9) use despite physical or
psychological problems
(10) tolerance
(11) withdrawal

Benzodiazepine Intoxication
Onset during or shortly after use

Benzodiazepine Withdrawal
Onset following cessation or reduction in
prolonged use

•

(1)

•

•

“clinically significant maladaptive
behavioral or psychological
changes (e.g., inappropriate sexual
or aggressive behavior, mood
lability, impaired judgment)”
at least 1 sign/symptom:
(1)
(2)
(3)
(4)
(5)
(6)

slurred speech
incoordination
unsteady gate
nystagmus
impaired cognition
(e.g., attention, memory)
stupor or coma

•

“clinically significant distress or
impairment in social, occupational,
or other important areas
of functioning”
at least 1 sign/symptom:
(1)
(2)
(3)
(4)
(5)

(6)
(7)
(8)

autonomic hyperactivity
(e.g., sweating, tachycardia)
hand tremor
insomnia
nausea or vomiting
transient visual, tactile,
or auditory hallucinations
or illusions
psychomotor agitation
anxiety
grand mal seizures
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3.4. Drug–Drug Interactions
Pharmacodynamically, the most significant concern with BZDs is CNS/respiratory depression.
Therefore BZDs are contraindicated with other CNS depressants. This is particularly concerning
since many people with anxiety have comorbid SUD, often with CNS depressants like alcohol,
opioids, ketamine, and marijuana. The CNS depressants considered to have “major” interactions
(i.e., concomitant use may cause respiratory depression, hypotension, profound sedation and
death) are: Barbiturates (such as butalbital, which is sometimes found in headache medicine),
cannabinoids, ethanol, melatonin (which has also been found to increase BZD binding at receptor sites),
opioids and opiate agonists (e.g., tramadol, buprenorphine), pramipexole, and sodium oxybate [74].
Despite these contraindications, significant predictors of BZD prescription rates include concurrent
opioid analgesic [23,26] and concurrent BZD prescriptions [26]. “Moderate” interactions include:
Anticonvulsants, antihistamines and antipsychotics (all of which are commonly used in mental health
patients). Regarding opioids and BZDs, one should typically be discontinued during the administration
of the other. A common scenario is a patient undergoing both alcohol/sedative withdrawal and opioid
withdrawal, during which the former is life-threatening and the latter is not, and therefore a BZD taper
should be favored over buprenorphine/methadone administration. However, the risks of delaying
opioid agonist treatment often outweighs the concerns about synergistic CNS depressant effects.
When the risks of delay outweigh the benefits, opioid dependent patients may be relatively safely
stabilized with agonists while also tapering benzodiazepines. Because of the exponential risk of
respiratory depression and death with concomitant use of BZDs and opioids these agents should only
be used together with abundant caution (e.g., prescribed at lower than usual doses) and only after
exhausting other options. Medications such as pseudoephedrine, phenylephrine and caffeine may
have minor-moderate drug interactions with BZDs because they antagonize the sedative effects of
BZDs [74], which could lead to some patients taking more BZDs to counteract the stimulants.
BZDs can be differentiated based on pharmacokinetic properties. Lorazepam, oxazepam and
temazepam are only metabolized via glucuronidation but not oxidation through the Cytochrome
P450 (CYP) pathway. Otherwise, BZDs are CYP3A4 substrates, though some can also be CYP2C19
substrates and CYP3A4 inhibitors. Medications that have a “major” potential to increase BZD levels
are: Aprepitant, atazanavir, boceprevir, ceritinib, chloramphenicol, cobicistat, conivaptan, darunavir,
dehydroepiandrosterone, delavirdine, fluvoxamine, fosamprenavir, fosaprepitant, grapefruit juice,
idelalisib, imatinib, indinavir, itraconazole, ketoconazole, lopinavir, nefazodone, nelfinavir, ritonavir,
saquinavir, telithromycin, and tipranavir [74]. Of this list, fluvoaxime and nefazodone are particularly
concerning as they are psychotropic medications. Conversely, BZDs may increase the levels of:
Cisapride (arrhythmia risk) and lomitapide (hepatotoxicity risk). Finally, BZD levels may be reduced
by: St. John’s Wort (an over-the-counter psychotropic commonly used for anxiety and/or depression).
4. Alternatives
BZDs are often used as first-line treatments for anxiety and insomnia despite evidence supporting
equal or superior efficacy of other treatment modalities that are less associated with toxicity (e.g., behavioral
therapy for insomnia, antidepressants for anxiety) [52–54]. There are several evidence-based alternatives
for BZDs for both fast-acting/acute and chronic uses. Regardless, of the treatment used, response
should be monitored and determined based, not only on self-reported symptom changes but also
functional improvement. Recovery should be equated with “adaptation, reappraisal, and learning” [7].
Reduced anxiety and increased sleep in the presence of sedative-induced emotional numbness and
detachment, and sedative-facilitated avoidance of healthy relationships and employment do not
denote recovery.
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4.1. First-Line Treatments for Anxiety and Insomnia
Psychotherapy (e.g., CBT, exposure, relaxation, eye movement desensitization and reprocessing
(EMDR)) is the gold standard treatment for anxiety while medications are generally considered
adjunctive (only serotonergic agents are considered first-line pharmacologic monotherapies) [36,44,55].
Nevertheless, patients with anxiety are frequently prescribed medications that are not evidence-based
or supported by CPGs, and BZDs are often initiated before evidence-based treatments are even tried
or offered. While serotonergic agents have stronger efficacy for anxiety than BZDs, it is notable that a
2016 Cochrane review [56] concluded insufficient evidence exists to compare antidepressants to BZDs
for the treatment of PD in terms of efficacy and tolerability.
For insomnia, psychological and behavioral therapies (e.g., CBT including CBT for insomnia
(CBT-I), stimulus control, relaxation, sleep restriction) are the standard of care. Medications, at best,
received a “consensus” or “weak” recommendation—each the lowest recommendation from respective
insomnia CPGs [37,57]—with temazepam and triazolam being the only BZDs to receive such a
recommendation and, then, only for short-term use. Nevertheless, insomnia patients are frequently
prescribed BZDs before gold standard treatments (i.e., psychological and behavioral) or even other
evidence-based medications (e.g., ramelteon, doxepin, suvorexant) [37,57].
Because of the wide spectrum of symptoms and the varying pathophysiological components behind
mental disorders, there are no panaceas. However, while first-line treatment (e.g., psychotherapy, SSRIs)
fail to control all symptoms in all people, unlike BZDs, they do not exacerbate the symptoms and
disorders they are not effective in treating.
4.2. Additional Pharmacologic Alternatives
Serotonergic agents (e.g., SSRIs, SNRIs, tricyclics, mirtazapine, monoamine oxidase inhibitors,
trazodone, nefazodone, buspirone) have the strongest evidence of greater therapeutic effects and less
adverse effects than BZDs, but adrenergic inhibitors (e.g., propranolol, prazosin, clonidine, guanfacine),
antihistamines (e.g., hydroxyzine, diphenhydramine), anticonvulsants (e.g., gabapentin, pregabalin,
lamotrigine, topiramate, valproate), antipsychotics (e.g., quetiapine, olanzapine, risperidone),
memantine and triiodothyronine all have stronger evidence for certain anxiety/insomnia disorders
than BZDs [19,31,33,35,36,38–45]. Consideration for unique adverse effects and comorbidities should
be given. For example: Hydroxyzine may be particularly effective for people with anxiety, insomnia,
nausea/vomiting and/or allergies (all indications); amitriptyline may be particularly effective for
people with anxiety, insomnia, depression, neuralgias and/or migraines (all indications); clonidine
may be particularly effective for people with anxiety, insomnia, inattention +/− attention-deficit
hyperactive disorder, tics, cancer-related pain, and/or hypertension (all indications); lamotrigine
may not be first-line but may be used earlier in the course of successive medication trials for people
with anxiety, bipolar disorder (especially bipolar depression), and epilepsy (both indications), and/or
obesity (lack of weight gain effects); and it may be prudent to avoid (or try later in the course of
medication trials) olanzapine in those with obesity and/or diabetes (metabolic risks) but useful to try
it earlier in those with anxiety, insomnia, depression, psychosis and/or bipolar disorder.
5. Conclusions
Overwhelming evidence for or against the use of BZDs is lacking for most psychiatric disorders.
What is known is the potential for rapid anxiolysis and sedation with these medications, though
long-term, outcome-based studies are needed. The potential for abuse and addiction is high with BZDs
and should be a consideration each time they are prescribed. Due to the lack of evidence of efficacy and
presence of evidence of many risks, BZD prescription is only recommended in severe, disabling anxiety
or insomnia. Until questions about long-term BZD use are satisfactorily addressed, “the wise prescriber
will limit his prescriptions in number to patients who are severely anxious or insomniac; in dosage to
the lowest effective; and in duration to a few weeks rather than months or years” [15]. Long-term BZD
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use has no efficacy and significant harm. “The risk/benefit ratio of these drugs becomes less favorable
or even adverse as treatment becomes prolonged: Efficacy wanes and risks accumulate” [15]. Risks
include dependence, withdrawal, “chronic subtle toxicity and the interference with the underlying
psychopathology” [8]. Their greatest asset is also their greatest liability: Drugs that work immediately
tend to be addictive” [82]. Without strong evidence of efficacy and with significant evidence of risks,
a variety of evidence-based treatments should be considered prior to initiating BZD trials. Assessment
of recovery should be based on improved functioning and not merely self-reported sedation (which
often does not correlated with functional recovery).
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